MMP-1 expression has an independent prognostic value in breast cancer

BMC Cancer

Table 1 Patients and tumour characteristics

Variable	Number of patients (%)
Number of the patients	125 (aged 30-90, mean 57, 5)
Grade
I	10 (8%)
II	66 (52, 8%)
III	49 (39, 2%)
Axillary nodal status
N0	64 (51, 2%)
≥N1	50 (40%)
Unknown	11 (8, 8%)
Estrogen receptor status (ER) ¹⁾
Positive	80 (64%)
Negative	45 (36%)
Progesterone receptor status (PR) ¹⁾
Positive	82 (65, 6%)
Negative	43 (34, 4%)
Ki-67 status ²⁾
low ≤ 15%	63 (50,4%)
intermediate 16-30%	41 (32,8%)
high > 30%	20 (16%)
one value missing	1 (8%)
Histologic type
Ductal	110 (88%)
Lobular	10 (8%)
Subtypes	5 (4%)
Her2 ³⁾
IHC positive (2+ and 3+)	25 (20%)
IHC negative (0 and 1+)	100 (80%)
CK 5/6 ⁴⁾
Triple-negative (ER-, PR-, Her2-)	35 (28%)
Basal-like carcinoma (ER-, PR-, Her2-, CK5/6+)	20 (16%)
Treatment after operation
Chemotherapy 27	(21,6%)
Radiation 59	(47,2%)
Hormonal therapy 24	(19,2%)

^1,4) Cut off point used for ER and PR immunohistochemistry is 10% of positively stained tumour nuclei and 10% cytoplasmic staining for CK5/6.
²⁾ Proliferation index according to St Gallen Consesus (Goldhirsch et al 2009).
³⁾ Scoring of HER2 immunohistochemistry: Score 0: no staining is observed or cell membrane staining is observed in less than 10% of tumour cells. Score 1+: a faint perceptible membrane staining can be detected in more than 10% of the tumour cells or cells are only stained in part of their membrane. Score 2+: a weak to moderate complete membrane staining is observed in more than 10% of the tumour cells. Score 3+: a strong complete membrane staining is observed in more than 10% of the tumour cells.

ISSN: 1471-2407